Cargando…

VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction

Neoantigens are tumor-specific antigens able to induce T-cell responses, generated by mutations in protein-coding regions of expressed genes. Previous studies demonstrated that only a limited subset of mutations generates neoantigens in microsatellite stable tumors. We developed a method, called VEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Leoni, Guido, D’Alise, Anna Morena, Tucci, Fabio Giovanni, Micarelli, Elisa, Garzia, Irene, De Lucia, Maria, Langone, Francesca, Nocchi, Linda, Cotugno, Gabriella, Bartolomeo, Rosa, Romano, Giuseppina, Allocca, Simona, Troise, Fulvia, Nicosia, Alfredo, Lahm, Armin, Scarselli, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402534/
https://www.ncbi.nlm.nih.gov/pubmed/34452005
http://dx.doi.org/10.3390/vaccines9080880
Descripción
Sumario:Neoantigens are tumor-specific antigens able to induce T-cell responses, generated by mutations in protein-coding regions of expressed genes. Previous studies demonstrated that only a limited subset of mutations generates neoantigens in microsatellite stable tumors. We developed a method, called VENUS (Vaccine-Encoded Neoantigens Unrestricted Selection), to prioritize mutated peptides with high potential to be neoantigens. Our method assigns to each mutation a weighted score that combines the mutation allelic frequency, the abundance of the transcript coding for the mutation, and the likelihood to bind the patient’s class-I major histocompatibility complex alleles. By ranking mutated peptides encoded by mutations detected in nine cancer patients, VENUS was able to select in the top 60 ranked peptides, the 95% of neoantigens experimentally validated including both CD8 and CD4 T cell specificities. VENUS was evaluated in a murine model in the context of vaccination with an adeno vector encoding the top ranked mutations prioritized in the MC38 cell line. Efficacy studies demonstrated anti tumoral activity of the vaccine when used in combination with checkpoint inhibitors. The results obtained highlight the importance of a combined scoring system taking into account multiple features of each tumor mutation to improve the accuracy of neoantigen prediction.